Medicina interna
Especialidad
Hospital Severo Ochoa
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Severo Ochoa (19)
2024
-
Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain
AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314
2023
-
HIV medical care interruption among people living with HIV in Spain, 2004-2020
AIDS, Vol. 37, Núm. 8, pp. 1277-1284
2022
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
-
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study
Medicine (United States), Vol. 101, Núm. 24, pp. E29252
-
Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort
HIV Medicine, Vol. 23, Núm. 8, pp. 825-836
-
Recomendaciones para el manejo de la hiperpotasemia en urgencias
Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias, Vol. 34, Núm. 4, pp. 287-297
2021
-
Author Correction: Identification of CRF89_BF, a new member of an HIV-1 circulating BF intersubtype recombinant form family widely spread in South America (Scientific Reports, (2021), 11, 1, (11442), 10.1038/s41598-021-90023-x)
Scientific Reports
-
Identification of CRF89_BF, a new member of an HIV-1 circulating BF intersubtype recombinant form family widely spread in South America
Scientific Reports, Vol. 11, Núm. 1
2019
-
Diverse large HIV-1 non-subtype B clusters are spreading among men who have sex with men in Spain
Frontiers in Microbiology, Vol. 10, Núm. APR
2017
-
Dual Therapy with Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy with Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial
Clinical Infectious Diseases, Vol. 65, Núm. 12, pp. 2112-2118
2016
-
Incidence and clearance of anal high-risk human papillomavirus in HIV-positive men who have sex with men: Estimates and risk factors
AIDS, Vol. 30, Núm. 1, pp. 37-44
2015
-
Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus
Clinical Infectious Diseases, Vol. 60, Núm. 6, pp. 950-958
2014
-
Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis
Journal of Acquired Immune Deficiency Syndromes, Vol. 66, Núm. 3, pp. 280-287
-
Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 9, pp. 583-597
-
Resumen ejecutivo del documento de consenso sobre el manejo de la patología renal en pacientes con infección por VIH
Nefrologia, Vol. 34, Núm. 6, pp. 768-788
2011
-
Documento de Consenso del Grupo de Estudio del Sida (GESIDA)/Plan Nacional sobre el Sida (PNS) sobre las infecciones de transmisión sexual en pacientes con infección por el VIH
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 29, Núm. 4
-
Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus
Journal of Antimicrobial Chemotherapy, Vol. 66, Núm. 12, pp. 2843-2849
2008
-
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903
Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092
2005
-
Treatment-limiting toxicities associated with nucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study
Current Therapeutic Research - Clinical and Experimental, Vol. 66, Núm. 2, pp. 117-129